Key findings from the ARC-20 casdatifan study
- Oral HIF-2α inhibitor casdatifan produced a 35% confirmed objective response rate in advanced clear cell renal cell carcinoma patients who received the recommended dose.
- Across all 127 heavily pre-treated study participants in the full trial population, the confirmed objective response rate reached 31%, with an overall disease-control rate exceeding 80%.
- Laboratory measurements indicated that drops in serum erythropoietin levels correlated with higher response rates, slower disease progression, and longer progression-free survival.
- Main side effects included anemia, fatigue, and hypoxia, which clinical staff managed through supportive care and dose adjustments without any treatment-related deaths.
Key trial metrics from the Nature publication
| Metric | Reported Result / Value |
|---|---|
| Investigational Drug | Casdatifan (HIF-2α inhibitor) |
| Target Indication | Advanced clear cell renal cell carcinoma (ccRCC) |
| Trial Identifier & Design | ARC-20 (Phase 1, single-arm, multi-center, NCT05536141) |
| Total Enrolled Population | 127 heavily pre-treated patients |
| Response Rate (Recommended Dose) | 35% confirmed objective response rate |
| Response Rate (Full Population) | 31% confirmed objective response rate |
| Overall Disease-Control Rate | >80% (includes stable disease) |
| Median Time to Response | Approximately 3 months |
| Peer-Reviewed Journal | Nature (published July 1, 2026, DOI: 10.1038/s41586-026-10718-x) |
Trial results published in Nature demonstrate durable tumor shrinkage
Clinical research published in Nature on July 1, 2026, details findings from the Phase 1 ARC-20 trial evaluating casdatifan in adults with advanced kidney cancer. The trial focused on clear cell renal cell carcinoma, an aggressive form of kidney cancer that had progressed despite multiple prior therapies. Led by Toni K. Choueiri, Jamie Merchan, Amita Patnaik, and a multi-institutional team of researchers, the trial tested the investigational drug across 127 heavily pre-treated participants.
Casdatifan is an orally bioavailable drug designed to selectively block hypoxia-inducible factor-2α (HIF-2α). In the trial subgroup receiving the recommended drug dose, casdatifan achieved a confirmed objective response rate of 35%. When looking across the entire 127-patient cohort, the confirmed response rate stood at 31%.
Tumor responses were not short-lived. The disease-control rate, which accounts for both partial responses and stable disease, exceeded 80%. On average, patients experienced a median time to response of approximately 3 months. Investigators observed that tumor shrinkage continued past the initial response assessment, showing no early plateau in treatment effect.
Understanding clear cell renal cell carcinoma and HIF-2α biology
Clear cell renal cell carcinoma represents approximately 75% of all kidney cancer diagnoses. In healthy tissue, proteins respond to oxygen levels to keep cellular growth balanced. But in clear cell kidney tumors, genetic alterations, such as the loss of the Von Hippel-Lindau (VHL) tumor-suppressor gene, lead to an abnormal accumulation of HIF-2α.
HIF-2α acts like an unmanaged biological accelerator. It flips on cellular switches that tell the tumor to grow new blood vessels, survive low-oxygen environments, and metastasize. Standard therapies often rely on immune-checkpoint inhibitors (targeting PD-1 or PD-L1) or anti-angiogenic vascular endothelial growth factor tyrosine-kinase inhibitors (VEGF-TKIs). While these standard options improve survival initially, many tumors develop resistance over time.
Casdatifan enters this landscape as a new generation small-molecule HIF-2α blocker. It was designed with pharmacologic properties intended to penetrate tumor tissue more effectively than early drugs in this class, such as belzutifan (Welireg). By binding to HIF-2α, casdatifan works to cut off the genetic signals driving tumor proliferation.
Serum erythropoietin drops confirm drug activity in tumor cells
To verify that casdatifan was hitting its target inside body tissues, trial investigators tracked specific biological markers. One key marker was serum erythropoietin, a hormone directly regulated by HIF-2α signaling.
Reductions in serum erythropoietin levels strongly linked to clinical benefit. Patients who experienced greater drops in this biomarker showed higher tumor response rates, slower cancer progression, and longer progression-free survival. In addition, tumors expressing higher baseline levels of HIF-2α biological activity proved more likely to shrink under treatment.
The multi-center ARC-20 trial (registered under NCT05536141) built upon earlier human testing. A prior Phase 1 trial in healthy volunteers, known as ARC-14, had previously evaluated the drug’s basic pharmacokinetics and pharmacodynamics. ARC-20 applied those early observations directly to patients with advanced, treatment-resistant disease.
Safety profile and clinical commentary from study investigators
Safety monitoring during the ARC-20 trial showed that casdatifan was generally manageable. The most common treatment-emergent adverse events were anemia, fatigue, and hypoxia. Trial clinicians addressed these events using supportive care interventions and protocol-guided dose adjustments.
Discontinuation of casdatifan due to treatment side effects occurred infrequently. No treatment-related deaths were reported during the trial period.
Dr. Jamie Merchan, study co-author, Professor of Medical Oncology, and Director of the Phase 1 Clinical Trials Program at the University of Miami Miller School of Medicine’s Sylvester Comprehensive Cancer Center, commented on the outcome: “These results are notable in a heavily pretreated population.”
Dr. Merchan added: “These findings are encouraging and suggest we may be able to better understand which patients benefit from targeting this pathway.” He noted that “This is an important step in understanding how tumor biology may help guide treatment decisions,” explaining that “In a disease that can shift and adapt over time, even a clearer line of sight into its underlying biology represents meaningful progress, helping guide where research and treatment strategies move next.”
Reading the Phase 1 trial results with appropriate caution
Phase 1 clinical trials are early exploratory studies. The ARC-20 study was conducted as a single-arm trial, meaning every participant received casdatifan without a direct control group or placebo comparison arm.
Because the trial lacked a comparator arm, clinicians cannot directly evaluate how casdatifan performs head-to-head against standard care or existing approved agents like belzutifan. Cross-trial comparisons remain limited due to differences in patient selection and study design. The trial report did not specify the exact milligram figure for the recommended dosage group.
Casdatifan remains an investigational agent. It has not received regulatory approval from health agencies and is not part of standard kidney cancer care guidelines. Future research will focus on ongoing clinical trials examining casdatifan in combination with other therapeutic agents.
Sources:
- Technology Networks, “Phase 1 Trial Results Highlight Casdatifan’s Potential in Kidney Cancer” (https://www.technologynetworks.com/tn/news/phase-1-trial-results-highlight-casdatifans-potential-in-kidney-cancer-415111)
- EurekAlert!, “Study: Casdatifan demonstrates durable tumor responses in heavily pretreated patients with advanced kidney cancer” (https://www.eurekalert.org/news-releases/1137816)
- Nature, “Casdatifan shows durable response linked to HIF-2α biology in kidney cancer” (https://www.nature.com/articles/s41586-026-10718-x)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.